BSX Stock Looks To Snap 3-Week Winning Streak: Analysts Downgrade Boston Scientific As Cyberattack And Slowing Growth Cloud Outlook
Boston Scientific (BSX) stock may end a 3-week rally as analysts downgrade it post-Q3 results and a weaker 2026 outlook. Jefferies and JPMorgan cut price targets to $46, citing cyberattack fallout, slowing growth, and delayed product pipelines. BSX reduced its full-year earnings forecast to $3.16-$3.18 per share from $3.28-$3.32. The stock is down 7% this week and 55% year-to-date.
How this was made
The 30-second read
Why it matters
The combined downgrade and guidance cut are likely to trigger sell pressure, especially in pre‑market trading, as investors reassess valuation multiples.
Market read
BSX's guidance downgrade and price‑target cuts are fresh, material news that can move the stock lower in the short term.
What to watch
Potential upside from upcoming product launches in 2028 and any resolution of the cyber‑security issue could mitigate the short‑term downside.
Background
Boston Scientific reported Q3 earnings that beat expectations but warned of slower growth, a cyberattack fallout, and delayed product milestones, prompting analyst downgrades.
Ticker impact
Jefferies and JPMorgan downgraded Boston Scientific (BSX) and cut price targets to $46, while the company lowered its full‑year adjusted earnings outlook to $3.16‑$3.18 per share.
likely downward pressure as investors price in weaker outlook and lower targets
Analyst rating changes and explicit earnings guidance reduction are fresh, material information that typically drives the stock lower on the day of release.
Market effects
Medical device sector may face broader scrutiny as a leading player signals slower growth and cyber‑risk exposure.
U.S. healthcare stocks could see modest pullback in early trading.
Limited to U.S. and international investors tracking Boston Scientific's pipeline and cyber‑security concerns.
Counterpoint
If the cyber‑incident impact is overstated, the stock could rebound on the back of its Q3 beat and long‑term pipeline potential.
Key entities
- CompanyBoston Scientific Corp.
Medical device manufacturer (ticker BSX).
- AnalystJefferies
Downgraded BSX to Hold and cut price target to $46.
- AnalystJPMorgan
Shifted rating to Neutral and cut price target to $46.
